CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM)

SIMPLE SUMMARY: In about 15–18% of breast cancers the HER2 gene is amplified, which allows an anti-HER2 treatment. However, about 50% of HER2-positive patients experience de novo or acquired resistance to the antibody-based therapy with trastuzumab. Therefore, the identification of predictive marker...

Descripción completa

Detalles Bibliográficos
Autores principales: Wege, Anja Kathrin, Dreyer, Tobias F., Teoman, Attila, Ortmann, Olaf, Brockhoff, Gero, Bronger, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158361/
https://www.ncbi.nlm.nih.gov/pubmed/34070094
http://dx.doi.org/10.3390/cancers13102459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158361/
https://www.ncbi.nlm.nih.gov/pubmed/34070094
http://dx.doi.org/10.3390/cancers13102459

Ejemplares similares